| 1 |
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl et al. · New England Journal of Medicine
Open access |
30 Sep 2015 |
826 |
| 2 |
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz, Craig L. Leonardi, Giampiero Girolomoni et al. · Journal of the American Academy of Dermatology
|
14 May 2015 |
210 |
| 3 |
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment ( SCULPTURE Extension Study)
Robert Bissonnette, Thomas Anton Luger, Diamant Thaçi et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
14 Feb 2018 |
200 |
| 4 |
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population
Kim Alexander Papp, Yves P. Poulin, Robert Bissonnette et al. · Journal of the American Academy of Dermatology
|
21 Sep 2010 |
101 |
| 5 |
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study
Robert Bissonnette, Thomas Anton Luger, Diamant Thaçi et al. · British Journal of Dermatology
|
5 Jun 2017 |
70 |
| 6 |
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis
Matthew Zirwas et al. · JAMA Dermatology
Open access |
3 May 2023 |
39 |
| 7 |
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
Robert Bissonnette, Jennifer Soung, Adelaide Ann Hebert et al. · New England Journal of Medicine
|
5 Nov 2025 |
31 |
| 8 |
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
Yan Ping Zhao, Melinda Gooderham, Bin Yang et al. · JAMA Dermatology
Open access |
30 Apr 2025 |
23 |
| 9 |
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
Linda Stein Gold et al. · Journal of the American Academy of Dermatology
|
29 Mar 2024 |
19 |
| 10 |
A fixed-dose combination of adapalene 0.1%–BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne
Robert Thomas Brodell, Bethanee J. Schlosser, Elyse S. Rafal et al. · Journal of Dermatological Treatment
|
21 Nov 2011 |
18 |
| 11 |
Long-term efficacy of up to 15 months’ efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis
Darryl P. Toth, Kim Alexander Papp, David Gratton · Dermatologic Therapy
Open access |
Nov 2008 |
6 |
| 12 |
An illustrative case of hypopigmented mycosis fungoides
Karen Michael, Annie R. Langley · SAGE Open Medical Case Reports
Open access |
31 Jul 2025 |
2 |
| 13 |
X-ray light valve (XLV): a novel detectors' technology for digital mammography
Sorin Marcovici, Vlad Sukhovatkin, Peter Oakham · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE
Conference paper |
19 Mar 2014 |
1 |
| 14 |
52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial
Yan Zhao, Melinda Gooderham, Bin Yang et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
2 Sep 2026 |
0 |
| 15 |
« Super-réponse » après traitement par delgocitinib 20 mg/g en crème dans un sous-groupe de patients atteints d’eczéma chronique des mains modéré à sévère
C. Bernier, April W. Armstrong, Robert Bissonnette et al. · Annales de Dermatologie et de Vénéréologie - FMC
|
13 Nov 2025 |
0 |
| 16 |
054 Treatment with ixekizumab over 60 weeks provides sustained improvements in health-related quality of life: Results from UNCOVER-1, a randomized phase 3 trial
Richard G B Langley, Steven R. Feldman, Carle F. Paul et al. · Journal of Investigative Dermatology
Open access |
16 Aug 2016 |
0 |